Our previous study has demonstrated that activated AMPK increases the efficacy of gefitinib on bladder cancer cells, related to metabolism‐associated Warburg effect.27 Furthermore, Li et al28 showed that PKM2 inhibitor reverses AMPK activity. Here, PKM is linked to urinary bladder carcinoma.